Dr. Reddy’s Laboratories Ltd experienced a decline in share price following a downgrade and the discontinuation of a significant clinical trial.
Reaction from the field
Dr. Reddy’s Laboratories Ltd stock closed at Rs 1,293 after a 0.84% decline, reflecting growing investor concerns following a series of negative developments. The pivotal event was MarketsMOJO’s downgrade on March 9, shifting the Mojo Grade to Sell with a score of 48.0. This downgrade was driven by deteriorating technicals and Q3 FY26 results that showed an 18.3% drop in Profit Before Tax and a 16.2% decrease in Profit After Tax.
Compounding these issues, the TACTI-004 Phase III trial was discontinued on March 16, 2026. This trial targeted advanced solid tumors, and halting it eliminates a potential near-term catalyst for the company, amplifying focus on its core generics and biosimilars pipeline. Investors are now left to assess the implications of this discontinuation on future growth prospects.
Despite these setbacks, Dr. Reddy’s reported a Q3 FY26 revenue increase of 4.4% year-over-year, amounting to Rs 8,716.8 crore. However, net profit for the same quarter fell by 14.4% to Rs 1,209.8 crore. The global generics revenue did rise by 7% to Rs 7,911.3 crore, indicating some resilience in its core business, although the overall financial performance has raised questions about the company’s operational efficiency.
The stock trades at a P/E ratio of 19.79, which is below the sector average of 32.90, suggesting potential undervaluation. Additionally, Dr. Reddy’s maintains a low debt-to-equity ratio of 0.01 and a return on equity of 15.78%, which are positive indicators for long-term investors. The stock has returned 18.56% over the past year, outperforming the Sensex’s 2.55%, showcasing its relative strength in the market.
Currently, the stock is near its 52-week high of Rs 1,377.95, down 4.78% from that peak. Following the Q3 results, the stock’s price hovered around Rs 1,283-1,292, indicating a cautious sentiment among investors. For investors, this highlights segment divergence: robust emerging market traction versus ongoing pricing battles in the US, a common trap for generics companies.
As the market digests these developments, uncertainties remain regarding the future trajectory of Dr. Reddy’s Laboratories. The discontinuation of the TACTI-004 trial and the downgrade from MarketsMOJO have created a challenging environment for the company. Details remain unconfirmed regarding any strategic shifts that may be implemented in response to these challenges.
In summary, while Dr. Reddy’s Laboratories has demonstrated some resilience in its financial performance, the recent downgrade and trial discontinuation have raised significant concerns among investors. The company’s ability to navigate these challenges will be critical in determining its stock performance in the coming months.
